New COVID-19 vaccine shows promise in small trial
NCT ID NCT05279456
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 25 times
Summary
This study tested a protein-based COVID-19 vaccine called SpikoGen in 39 adults who had never received a COVID-19 vaccine. Participants got two doses one month apart, followed by a third booster dose either one or three months later. The goal was to see how well the vaccine triggered antibody production and to check for any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ARASMI
Adelaide, South Australia, 5042, Australia
Conditions
Explore the condition pages connected to this study.